{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T16:40:04Z","timestamp":1795192804971,"version":"4.10.3"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,6,8]],"date-time":"2023-06-08T00:00:00Z","timestamp":1686182400000},"content-version":"vor","delay-in-days":7,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Study Sponsor, Acadia Pharmaceuticals"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2023,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Rett syndrome is a rare, genetic neurodevelopmental disorder. Trofinetide is a synthetic analog of glycine\u2013proline\u2013glutamate, the N-terminal tripeptide of the insulin-like growth factor 1 protein, and has demonstrated clinical benefit in phase 2 studies in Rett syndrome. In this phase 3 study (\n                    <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\">https:\/\/clinicaltrials.gov<\/jats:ext-link>\n                    identifier\n                    <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04181723?term=NCT04181723&amp;draw=2&amp;rank=1\">NCT04181723<\/jats:ext-link>\n                    ), females with Rett syndrome received twice-daily oral trofinetide (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200993) or placebo (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200994) for 12 weeks. For the coprimary efficacy endpoints, least squares mean (LSM) change from baseline to week 12 in the Rett Syndrome Behaviour Questionnaire for trofinetide versus placebo was \u22124.9 versus \u22121.7 (\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.0175; Cohen\u2019s\n                    <jats:italic>d<\/jats:italic>\n                    effect size, 0.37), and LSM Clinical Global Impression\u2013Improvement at week 12 was 3.5 versus 3.8 (\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.0030; effect size, 0.47). For the key secondary efficacy endpoint, LSM change from baseline to week 12 in the Communication and Symbolic Behavior Scales Developmental Profile Infant\u2013Toddler Checklist Social Composite score was \u22120.1 versus \u22121.1 (\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.0064; effect size, 0.43). Common treatment-emergent adverse events included diarrhea (80.6% for trofinetide versus 19.1% for placebo), which was mostly mild to moderate in severity. Significant improvement for trofinetide compared with placebo was observed for the coprimary efficacy endpoints, suggesting that trofinetide provides benefit in treating the core symptoms of Rett syndrome.\n                  <\/jats:p>","DOI":"10.1038\/s41591-023-02398-1","type":"journal-article","created":{"date-parts":[[2023,6,8]],"date-time":"2023-06-08T12:01:46Z","timestamp":1686225706000},"page":"1468-1475","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":197,"title":["Trofinetide for the treatment of Rett syndrome: a randomized phase 3 study"],"prefix":"10.1038","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5628-5872","authenticated-orcid":false,"given":"Jeffrey L.","family":"Neul","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan K.","family":"Percy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy A.","family":"Benke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7099-1522","authenticated-orcid":false,"given":"Elizabeth M.","family":"Berry-Kravis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel G.","family":"Glaze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3264-0902","authenticated-orcid":false,"given":"Eric D.","family":"Marsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serge","family":"Stankovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathie M.","family":"Bishop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5551-8956","authenticated-orcid":false,"given":"James M.","family":"Youakim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,8]]},"reference":[{"key":"2398_CR1","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1002\/ana.22124","volume":"68","author":"JL Neul","year":"2010","unstructured":"Neul, J. L. et al. Rett syndrome: revised diagnostic criteria and nomenclature. Ann. Neurol. 68, 944\u2013950 (2010).","journal-title":"Ann. Neurol."},{"key":"2398_CR2","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1097\/MPG.0b013e31824b6159","volume":"55","author":"KJ Motil","year":"2012","unstructured":"Motil, K. J. et al. Gastrointestinal and nutritional problems occur frequently throughout life in girls and women with Rett syndrome. J. Pediatr. Gastroenterol. Nutr. 55, 292\u2013298 (2012).","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"2398_CR3","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/13810","volume":"23","author":"RE Amir","year":"1999","unstructured":"Amir, R. E. et al. Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2. Nat. Genet. 23, 185\u2013188 (1999).","journal-title":"Nat. Genet."},{"key":"2398_CR4","doi-asserted-by":"publisher","first-page":"18","DOI":"10.3389\/fncel.2014.00018","volume":"8","author":"G Baj","year":"2014","unstructured":"Baj, G., Patrizio, A., Montalbano, A., Sciancalepore, M. & Tongiorgi, E. Developmental and maintenance defects in Rett syndrome neurons identified by a new mouse staging system in vitro. Front. Cell. Neurosci. 8, 18 (2014).","journal-title":"Front. Cell. Neurosci."},{"key":"2398_CR5","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1093\/cercor\/bhv078","volume":"26","author":"F Bedogni","year":"2016","unstructured":"Bedogni, F. et al. Defects during Mecp2 null embryonic cortex development precede the onset of overt neurological symptoms. Cereb. Cortex 26, 2517\u20132529 (2016).","journal-title":"Cereb."},{"key":"2398_CR6","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1002\/cne.22009","volume":"514","author":"PV Belichenko","year":"2009","unstructured":"Belichenko, P. V. et al. Widespread changes in dendritic and axonal morphology in Mecp2-mutant mouse models of Rett syndrome: evidence for disruption of neuronal networks. J. Comp. Neurol. 514, 240\u2013258 (2009).","journal-title":"J. Comp. Neurol."},{"key":"2398_CR7","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1111\/j.1651-2227.1985.tb10993.x","volume":"74","author":"B Hagberg","year":"1985","unstructured":"Hagberg, B. Rett\u2019s syndrome: prevalence and impact on progressive severe mental retardation in girls. Acta Paediatr. Scand. 74, 405\u2013408 (1985).","journal-title":"Acta Paediatr. Scand."},{"key":"2398_CR8","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/ajmg.b.32707","volume":"180","author":"JL Neul","year":"2019","unstructured":"Neul, J. L. et al. The array of clinical phenotypes of males with mutations in methyl-CpG binding protein 2. Am. J. Med. Genet. B Neuropsychiatr. Genet. 180, 55\u201367 (2019).","journal-title":"Am. J. Med. Genet. B Neuropsychiatr. Genet."},{"key":"2398_CR9","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/1866-1955-6-20","volume":"6","author":"JL Neul","year":"2014","unstructured":"Neul, J. L. et al. Developmental delay in Rett syndrome: data from the Natural History Study. J. Neurodev. Disord. 6, 20 (2014).","journal-title":"J. Neurodev. Disord."},{"key":"2398_CR10","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1002\/mrdd.10020","volume":"8","author":"B Hagberg","year":"2002","unstructured":"Hagberg, B. Clinical manifestations and stages of Rett syndrome. Ment. Retard. Dev. Disabil. Res. Rev. 8, 61\u201365 (2002).","journal-title":"Ment. Retard. Dev. Disabil. Res. Rev."},{"key":"2398_CR11","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1002\/ana.22154","volume":"68","author":"AK Percy","year":"2010","unstructured":"Percy, A. K. et al. Rett syndrome diagnostic criteria: lessons from the Natural History Study. Ann. Neurol. 68, 951\u2013955 (2010).","journal-title":"Ann. Neurol."},{"key":"2398_CR12","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1093\/brain\/aww302","volume":"140","author":"DC Tarquinio","year":"2017","unstructured":"Tarquinio, D. C. et al. Longitudinal course of epilepsy in Rett syndrome and related disorders. Brain 140, 306\u2013318 (2017).","journal-title":"Brain"},{"key":"2398_CR13","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1097\/MPG.0000000000000200","volume":"58","author":"G Baikie","year":"2014","unstructured":"Baikie, G. et al. Gastrointestinal dysmotility in Rett syndrome. J. Pediatr. Gastroenterol. Nutr. 58, 237\u2013244 (2014).","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"2398_CR14","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.jns.2008.12.003","volume":"278","author":"MJ Bickerdike","year":"2009","unstructured":"Bickerdike, M. J. et al. NNZ-2566: a Gly\u2013Pro\u2013Glu analogue with neuroprotective efficacy in a rat model of acute focal stroke. J. Neurol. Sci. 278, 85\u201390 (2009).","journal-title":"J. Neurol. Sci."},{"key":"2398_CR15","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1358\/dof.2021.46.1.3208246","volume":"46","author":"BE Collins","year":"2021","unstructured":"Collins, B. E. & Neul, J. L. Trofinetide. Glycine\u2013proline\u2013glutamate (GPE) analogue, treatment of Rett syndrome, treatment of fragile X syndrome. Drugs Future 46, 29\u201342 (2021).","journal-title":"Drugs Future"},{"key":"2398_CR16","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.1073\/pnas.0812394106","volume":"106","author":"D Tropea","year":"2009","unstructured":"Tropea, D. et al. Partial reversal of Rett syndrome-like symptoms in MeCP2 mutant mice. Proc. Natl Acad. Sci. USA 106, 2029\u20132034 (2009).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2398_CR17","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.ab.2003.08.032","volume":"323","author":"DC Batchelor","year":"2003","unstructured":"Batchelor, D. C. et al. Pharmacokinetics of glycine\u2013proline\u2013glutamate, the N-terminal tripeptide of insulin-like growth factor-1, in rats. Anal. Biochem. 323, 156\u2013163 (2003).","journal-title":"Anal. Biochem."},{"key":"2398_CR18","doi-asserted-by":"publisher","first-page":"e1912","DOI":"10.1212\/WNL.0000000000007316","volume":"92","author":"DG Glaze","year":"2019","unstructured":"Glaze, D. G. et al. Double-blind, randomized, placebo-controlled study of trofinetide in pediatric Rett syndrome. Neurology 92, e1912\u2013e1925 (2019).","journal-title":"Neurology"},{"key":"2398_CR19","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1111\/1469-7610.00236","volume":"43","author":"RH Mount","year":"2002","unstructured":"Mount, R. H., Charman, T., Hastings, R. P., Reilly, S. & Cass, H. The Rett Syndrome Behaviour Questionnaire (RSBQ): refining the behavioural phenotype of Rett syndrome. J. Child Psychol. Psychiatry 43, 1099\u20131110 (2002).","journal-title":"J. Child Psychol. Psychiatry"},{"key":"2398_CR20","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1177\/0883073815579707","volume":"30","author":"JL Neul","year":"2015","unstructured":"Neul, J. L. et al. Improving treatment trial outcomes for Rett syndrome: the development of Rett-specific anchors for the Clinical Global Impression Scale. J. Child Neurol. 30, 1743\u20131748 (2015).","journal-title":"J. Child Neurol."},{"key":"2398_CR21","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.pediatrneurol.2017.07.002","volume":"76","author":"DG Glaze","year":"2017","unstructured":"Glaze, D. G. et al. A double-blind, randomized, placebo-controlled clinical study of trofinetide in the treatment of Rett syndrome. Pediatr. Neurol. 76, 37\u201346 (2017).","journal-title":"Pediatr. Neurol."},{"key":"2398_CR22","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1002\/pds.1211","volume":"15","author":"R Temple","year":"2006","unstructured":"Temple, R. Hy\u2019s law: predicting serious hepatotoxicity. Pharmacoepidemiol. Drug Saf. 15, 241\u2013243 (2006).","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"2398_CR23","unstructured":"Cohen, J. Statistical Power Analysis for the Behavioral Sciences (Lawrence Erlbaum Associates, 1988)."},{"key":"2398_CR24","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s11689-015-9127-4","volume":"7","author":"KV Barnes","year":"2015","unstructured":"Barnes, K. V. et al. Anxiety-like behavior in Rett syndrome: characteristics and assessment by anxiety scales. J. Neurodev. Disord. 7, 30 (2015).","journal-title":"J. Neurodev. Disord."},{"key":"2398_CR25","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s11689-015-9104-y","volume":"7","author":"R Cianfaglione","year":"2015","unstructured":"Cianfaglione, R. et al. A national survey of Rett syndrome: behavioural characteristics. J. Neurodev. Disord. 7, 11 (2015).","journal-title":"J. Neurodev. Disord."},{"key":"2398_CR26","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1002\/ajmg.b.30270","volume":"141B","author":"L Robertson","year":"2006","unstructured":"Robertson, L. et al. The association between behavior and genotype in Rett syndrome using the Australian Rett Syndrome Database. Am. J. Med. Genet. B Neuropsychiatr. Genet. 141B, 177\u2013183 (2006).","journal-title":"Am. J. Med. Genet. B Neuropsychiatr. Genet."},{"key":"2398_CR27","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1111\/j.1365-2753.2007.00921.x","volume":"14","author":"M Berk","year":"2008","unstructured":"Berk, M. et al. The validity of the CGI severity and improvement scales as measures of clinical effectiveness suitable for routine clinical use. J. Eval. Clin. Pract. 14, 979\u2013983 (2008).","journal-title":"J. Eval. Clin. Pract."},{"key":"2398_CR28","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.comppsych.2008.08.005","volume":"50","author":"J Busner","year":"2009","unstructured":"Busner, J., Targum, S. D. & Miller, D. S. The Clinical Global Impressions scale: errors in understanding and use. Compr. Psychiatry 50, 257\u2013262 (2009).","journal-title":"Compr. Psychiatry"},{"key":"2398_CR29","first-page":"1043","volume":"4","author":"WE Kaufmann","year":"2016","unstructured":"Kaufmann, W. E., Stallworth, J. L., Everman, D. B. & Skinner, S. A. Neurobiologically-based treatments in Rett syndrome: opportunities and challenges. Expert Opin. Orphan Drugs 4, 1043\u20131055 (2016).","journal-title":"Expert Opin."},{"key":"2398_CR30","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1097\/DBP.0b013e31829d1f20","volume":"34","author":"E Berry-Kravis","year":"2013","unstructured":"Berry-Kravis, E. et al. Outcome measures for clinical trials in fragile X syndrome. J. Dev. Behav. Pediatr. 34, 508\u2013522 (2013).","journal-title":"J. Dev. Behav. Pediatr."},{"key":"2398_CR31","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s11689-017-9193-x","volume":"9","author":"DB Budimirovic","year":"2017","unstructured":"Budimirovic, D. B. et al. Updated report on tools to measure outcomes of clinical trials in fragile X syndrome. J. Neurodev. Disord. 9, 14 (2017).","journal-title":"J. Neurodev. Disord."},{"key":"2398_CR32","doi-asserted-by":"publisher","first-page":"106704","DOI":"10.1016\/j.cct.2022.106704","volume":"114","author":"JL Neul","year":"2022","unstructured":"Neul, J. L. et al. Design and outcome measures of LAVENDER, a phase 3 study of trofinetide for Rett syndrome. Contemp. Clin. Trials 114, 106704 (2022).","journal-title":"Contemp. Clin. Trials"},{"key":"2398_CR33","doi-asserted-by":"publisher","unstructured":"Neul, J. L., Benke, T. A., Marsh, E. D. et al. Top caregiver concerns in Rett syndrome and related disorders: data from the US Natural History Study. Preprint at Research Square https:\/\/doi.org\/10.21203\/rs.3.rs-2566253\/v1 (2023).","DOI":"10.21203\/rs.3.rs-2566253\/v1"},{"key":"2398_CR34","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.seizure.2005.12.009","volume":"15","author":"SN Ahmed","year":"2006","unstructured":"Ahmed, S. N. & Siddiqi, Z. A. Antiepileptic drugs and liver disease. Seizure 15, 156\u2013164 (2006).","journal-title":"Seizure"},{"key":"2398_CR35","unstructured":"Ryther, R. et al. Design and outcome measures of an open label study of trofinetide for the treatment of girls 2 to 5 years of age with Rett syndrome. Poster presented at ASCEND\/IRSF Rett Syndrome National Summit Nashville, TN, 27\u201330 April 2022."},{"key":"2398_CR36","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1038\/nrd.2017.221","volume":"17","author":"EM Berry-Kravis","year":"2018","unstructured":"Berry-Kravis, E. M. et al. Drug development for neurodevelopmental disorders: lessons learned from fragile X syndrome. Nat. Rev. Drug Discov. 17, 280\u2013299 (2018).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2398_CR37","doi-asserted-by":"publisher","first-page":"2740","DOI":"10.1007\/s10803-020-04381-y","volume":"50","author":"M Gomathi","year":"2020","unstructured":"Gomathi, M., Padmapriya, S. & Balachandar, V. Drug studies on Rett syndrome: from bench to bedside. J. Autism Dev. Disord. 50, 2740\u20132764 (2020).","journal-title":"J. Autism Dev. Disord."},{"key":"2398_CR38","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1044\/1092-4388(2002\/097)","volume":"45","author":"AM Wetherby","year":"2002","unstructured":"Wetherby, A. M., Allen, L., Cleary, J., Kublin, K. & Goldstein, H. Validity and reliability of the Communication and Symbolic Behavior Scales Developmental Profile with very young children. J. Speech Lang. Hear. Res. 45, 1202\u20131218 (2002).","journal-title":"J. Speech Lang. Hear. Res."},{"key":"2398_CR39","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1044\/2015_JSLHR-L-14-0185","volume":"59","author":"A Urbanowicz","year":"2016","unstructured":"Urbanowicz, A., Downs, J., Girdler, S., Ciccone, N. & Leonard, H. An exploration of the use of eye gaze and gestures in females with Rett syndrome. J. Speech Lang. Hear. Res. 59, 1373\u20131383 (2016).","journal-title":"J. Speech Lang. Hear. Res."},{"key":"2398_CR40","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1177\/1362361314542955","volume":"19","author":"E Anagnostou","year":"2015","unstructured":"Anagnostou, E. et al. Measuring social communication behaviors as a treatment endpoint in individuals with autism spectrum disorder. Autism 19, 622\u2013636 (2015).","journal-title":"Autism"},{"key":"2398_CR41","doi-asserted-by":"publisher","first-page":"e2594","DOI":"10.1212\/WNL.0000000000007560","volume":"92","author":"JL Stallworth","year":"2019","unstructured":"Stallworth, J. L. et al. Hand stereotypies: lessons from the Rett Syndrome Natural History Study. Neurology 92, e2594\u2013e2603 (2019).","journal-title":"Neurology"}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-023-02398-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-023-02398-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-023-02398-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,21]],"date-time":"2024-10-21T19:45:19Z","timestamp":1729539919000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-023-02398-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":41,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["2398"],"URL":"https:\/\/doi.org\/10.1038\/s41591-023-02398-1","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"10 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.L.N. has received research funding from the International Rett Syndrome Foundation, the National Institutes of Health and Rett Syndrome Research Trust; and personal consultancy fees from Acadia Pharmaceuticals, Analysis Group, AveXis, GW Pharmaceuticals, Hoffmann-La Roche, Myrtelle, Neurogene, Newron Pharmaceuticals, Signant Health and Taysha Gene Therapies and for the preparation of CME activities for Medscape and PeerView Institute; serves on the scientific advisory board of Alcyone Lifesciences; is a scientific cofounder of LizarBio Therapeutics; and was a member of a data safety monitoring board for clinical trials conducted by Ovid Therapeutics. A.K.P. is coeditor of <i>Translational Science of Rare Diseases<\/i>, received research funding from the National Institutes of Health and is a consultant for Acadia Pharmaceuticals, AveXis, GW Pharmaceuticals and Anavex Life Science as well as an adviser to the International Rett Syndrome Foundation. T.A.B. received research funding from the GRIN2B Foundation, the International Foundation for CDKL5 Research, the Loulou Foundation, the National Institutes of Health and the Simons Foundation; has consultancies for Alcyone, AveXis, GRIN Therapeutics, GW Pharmaceuticals, the International Rett Syndrome Foundation, Marinus Pharmaceuticals, Neurogene, Ovid Therapeutics and Takeda Pharmaceutical; has clinical trials with Acadia Pharmaceuticals, GW Pharmaceuticals, Marinus Pharmaceuticals, Ovid Therapeutics and Rett Syndrome Research Trust; all remuneration has been made to his department. E.M.B.-K. has received funding from Acadia Pharmaceuticals, Alcobra Pharmaceuticals, AMO Pharma, Asuragen, AveXis, Biogen, BioMarin, Cydan Development, EryDel, Fulcrum Therapeutics, GeneTx, GW Pharmaceuticals, Ionis Pharmaceuticals, Jaguar Health, Lumos Pharma, Marinus Pharmaceuticals, Neuren Pharmaceuticals, Neurogene, Neurotrope, Novartis, Orphazyme, Ovid Therapeutics, Retrophin, Roche, Seaside Therapeutics, Taysha Gene Therapies, Tetra Bio-Pharma, Ultragenyx, Yamo Pharmaceuticals, Zynerba Pharmaceuticals and Vtesse\u2013Sucampo\u2013Mallinckrodt Pharmaceuticals to consult on trial design or run clinical or laboratory validation trials in genetic neurodevelopmental or neurodegenerative disorders, all of which is directed to Rush University Medical Center in support of rare disease programs; E.M.B.-K. receives no personal funds, and Rush University Medical Center has no relevant financial interest in any of the commercial entities listed. D.G.G. has received personal compensation and research support from Acadia Pharmaceuticals, Neuren Pharmaceuticals and Newron Pharmaceuticals. E.D.M. has received research support from the National Institute of Neurological Disorders and Stroke and the National Institute of Child Health and Human Development, the Eagles Autism Foundation, Penn Orphan Disease Center, the International Rett Syndrome Foundation, Rett Syndrome Research Trust, the International CDKL5 Research Foundation and the Loulou Foundation. He has been a site principal investigator for trials from Stoke Therapeutics, GW Pharmaceuticals, Zogenix, Acadia Pharmaceuticals and Marinus Pharmaceuticals. He has received personal compensation for consulting from Stoke Therapeutics and Acadia Pharmaceuticals. J.M.Y., K.M.B., S.S. and T.L. are employees of and stockholders in Acadia Pharmaceuticals. S.S. is also a board director and stockholder of Neurogene.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}